Targeted therapy for Ewing's sarcoma: significance of heterogeneity

Area of Science:

• Oncology
• Molecular Pathology
• Cancer Genomics

Background:

• Ewing sarcoma (ES) has limited survival rates, necessitating novel therapeutic strategies.
• Targeted therapies for ES, such as insulin-like growth factor inhibitors, require precise identification of molecular tumor alterations.
• Tumor heterogeneity presents a challenge in selecting effective treatments for ES.

Purpose of the Study:

• To investigate tumor heterogeneity in Ewing sarcoma by assessing DNA content and ploidy.
• To evaluate the stability of ploidy over time and across different tumor lesions within individual patients.
• To determine the prognostic value of DNA ploidy in Ewing sarcoma.

Main Methods:

• DNA image cytometry (IC) was utilized on 41 samples from 21 ES patients.
• Ploidy status was analyzed for temporal and interlesional consistency.
• The association between ploidy and patient survival was statistically assessed.

Main Results:

• Significant variations in DNA content were observed over time and between different tumor sites within the same patient.
• Coexistence of multiple ploidy states was detected at single time points.
• Non-diploid DNA content correlated with significantly shorter overall survival (median 19 months vs. 84 months, p=0.047).

Conclusions:

• Ewing sarcoma exhibits dynamic changes and heterogeneity in DNA ploidy state.
• Relying on a single tumor sample for molecular screening may lead to inadequate or excessive treatment.
• Non-diploid DNA content serves as a marker for biologically distinct tumor clones and predicts an adverse outcome in ES.